CUE Cue Biopharma Inc
Price (delayed)
$0.58
Market cap
$28.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
$6.61M
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the
Highlights
CUE's debt is down by 38% year-on-year and by 13% since the previous quarter
The EPS is up by 23% YoY and by 8% QoQ
The company's equity has shrunk by 53% YoY and by 28% QoQ
Cue Biopharma's quick ratio has decreased by 45% YoY and by 16% QoQ
Key stats
What are the main financial stats of CUE
Market
Valuations
Earnings
Shares outstanding
48.64M
Market cap
$28.21M
Enterprise value
$6.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
3.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.8
Revenue
$8.3M
EBIT
-$45.71M
EBITDA
-$42.29M
Free cash flow
-$38.6M
Per share
Balance sheet
Liquidity
EPS
-$0.98
Free cash flow per share
-$0.77
Book value per share
$0.44
Revenue per share
$0.17
TBVPS
$0.84
Total assets
$42.33M
Total liabilities
$20.71M
Debt
$11.26M
Equity
$21.62M
Working capital
$17.44M
Debt to equity
0.52
Current ratio
2.06
Quick ratio
2.11
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-509.8%
Gross margin
100%
Net margin
-566%
Operating margin
-582.2%
Return on assets
-82.9%
Return on equity
-142.9%
Return on invested capital
-670.2%
Return on capital employed
-176.7%
Return on sales
-551%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CUE stock price
How has the Cue Biopharma stock price performed over time
Intraday
-1.59%
1 week
-7.94%
1 month
-11.71%
1 year
-78.68%
YTD
-78.03%
QTD
-53.23%
Financial performance
How have Cue Biopharma's revenue and profit performed over time
Revenue
$8.3M
Gross profit
$8.3M
Operating income
-$48.3M
Net income
-$46.96M
Gross margin
100%
Net margin
-566%
Cue Biopharma's operating margin has soared by 80% YoY and by 21% from the previous quarter
CUE's net margin has surged by 80% year-on-year and by 20% since the previous quarter
CUE's revenue is up by 18% since the previous quarter
The gross profit is up by 18% since the previous quarter
Growth
What is Cue Biopharma's growth rate over time
Valuation
What is Cue Biopharma stock price valuation
P/E
N/A
P/B
1.3
P/S
3.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.8
The EPS is up by 23% YoY and by 8% QoQ
The P/B is 70% below the 5-year quarterly average of 4.4 and 54% below the last 4 quarters average of 2.9
The company's equity has shrunk by 53% YoY and by 28% QoQ
The price to sales (P/S) is 95% lower than the 5-year quarterly average of 78.1 and 80% lower than the last 4 quarters average of 17.7
CUE's revenue is up by 18% since the previous quarter
Efficiency
How efficient is Cue Biopharma business performance
The ROS has soared by 81% YoY and by 21% QoQ
Cue Biopharma's return on equity has decreased by 50% YoY and by 11% QoQ
The ROIC has decreased by 44% QoQ
The ROA has contracted by 29% YoY and by 7% from the previous quarter
Dividends
What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CUE.
Financial health
How did Cue Biopharma financials performed over time
The total assets is 104% greater than the total liabilities
The current ratio has declined by 45% year-on-year and by 17% since the previous quarter
Cue Biopharma's quick ratio has decreased by 45% YoY and by 16% QoQ
CUE's debt is 48% smaller than its equity
The company's equity has shrunk by 53% YoY and by 28% QoQ
CUE's debt is down by 38% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.